Results 161 to 170 of about 8,070 (210)
Targeting the Glucose-Insulin Link in Head and Neck Squamous Cell Carcinoma Induces Cytotoxic Oxidative Stress and Inhibits Cancer Growth. [PDF]
Cancer Res CommunMazambani S +17 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Clinics in Rheumatic Diseases, 1984
It has been widely accepted for a number of years that chrysotherapy is a valuable therapeutic agent in the treatment of progressive rheumatoid disease. This therapeutic benefit has, to some extent, been offset by the potential toxicity associated with gold compounds. The development of a gold compound with a greater therapeutic to toxicity ratio would
M, Ferrari, M T, Piro
+7 more sources
It has been widely accepted for a number of years that chrysotherapy is a valuable therapeutic agent in the treatment of progressive rheumatoid disease. This therapeutic benefit has, to some extent, been offset by the potential toxicity associated with gold compounds. The development of a gold compound with a greater therapeutic to toxicity ratio would
M, Ferrari, M T, Piro
+7 more sources
Auranofin‐induced vasomotor reaction
Arthritis & Rheumatism, 1992AbstractVasomoto reactions after administraton of gold sodium thiomalate (GST)are well recognized, ut such reacti9os have not bn reported to ccur in assocation woth oral gold treatment. We descrbe a woman with rheumatoid arthritis who exprienced typical nitritoid reactions after treatment with GST, and later, with auranofin.
S M, Proudman, L G, Cleland
openaire +2 more sources
Roentgenographic findings during auranofin treatment
The American Journal of Medicine, 1983Roentgenograms of hands and wrists from rheumatoid arthritis patients treated with auranofin for 12 and 24 months were scored for severity of erosive disease. Scores were analyzed by a method in which a calculated mean annual rate of erosion prior to treatment was compared with the annualized rate during therapy.
J P, Gofton, W, O'Brien
openaire +2 more sources
The cellular pharmacology of auranofin
Seminars in Arthritis and Rheumatism, 1987A URANOFIN (AF) [SKF 39162; (l-thioB-D-glucopyranose 2,3,4,6_tetraacetatoS)(triethylphosphine)gold], an orally active chrysotherapeutic agent, has recently been registered in 43 countries for use in the treatment of rheumatoid arthritis (RA).‘,’ Although substantial amounts of information relating to the chemical, pharmacologic, and clinical aspects of
R M, Snyder, C K, Mirabelli, S T, Crooke
openaire +2 more sources
International Journal of Pharmaceutics, 1985
Abstract Two forms of auranofin, designated as A and B, have been identified. These two forms are identical in composition and differ only in their crystalline morphology. Contrary to usual expectations, form A, having the lower melting temperature, also has the lower apparent equilibrium solubility.
S LINDENBAUM +4 more
openaire +1 more source
Abstract Two forms of auranofin, designated as A and B, have been identified. These two forms are identical in composition and differ only in their crystalline morphology. Contrary to usual expectations, form A, having the lower melting temperature, also has the lower apparent equilibrium solubility.
S LINDENBAUM +4 more
openaire +1 more source
The American Journal of Medicine, 1983
Auranofin, an oral gold-containing medication for the treatment of rheumatoid arthritis, has unique chemical, pharmacologic, and kinetic characteristics. Clinical improvement is achieved with lower blood gold levels than with parenteral gold compounds.
openaire +2 more sources
Auranofin, an oral gold-containing medication for the treatment of rheumatoid arthritis, has unique chemical, pharmacologic, and kinetic characteristics. Clinical improvement is achieved with lower blood gold levels than with parenteral gold compounds.
openaire +2 more sources